ANI Pharmaceuticals, Inc. (ANIP)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$69.62-2.83%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
QuarterlyIQ Insights · ANIP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -38.6% |
| Our one-year growth estimate | diamond | -1.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 37.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 12 industry peers · Company calendar date is not available
ANIP — credit agreement
Dated 2026-11-05
Entry into a Material Definitive Agreement On Novemb er 4, 2 026, ANI Pharmaceuticals, Inc. (the “Company”) entered into a credit agreement (the “Credit Agreement”) relating to a 364-day senior bridge facility (the “Facility”), with the lenders named therein and JPMorgan Chase Bank, N.A, as administrative agent. The Facility provides for borrowings up to an aggregate principal amount of $676 million and matures 364 days after the initial day of funding, in each case, as further described in t…
Why it matters: The expanded team began reaching podiatrists and primary care doctors. More new patient cases would show demand is spreading.
Supportive ifThe next update reports continued growth in new gout patients. It also reports broad prescribing by podiatrists and primary care doctors.
Worry ifThe next update reports fewer new gout cases or a clear drop in the number of doctors starting treatment.
Why it matters: ANI had launched 12 Generics products by Q2 and was on track for at least 15 in 2026. The count tests launch execution.
Supportive ifANI reports at least 15 new Generics product launches in 2026. Q4 results or a company update confirms the count.
Worry ifANI reports fewer than 15 new Generics launches for 2026 or states that the launch goal was missed.
Why it matters: The board approved a $100 million repurchase plan, but Q2 results gave no amount bought. A reported total will show how much has been used.
Watch forANI reports share repurchases under the plan. It states the amount spent or the number of shares bought.
Also watch forANI reports no repurchases in Q3, or suspends or ends the program before its May 2029 end date.
Why it matters: Q2 sales grew 43.5%, but management lowered its full-year Cortrophin sales range. Q3 results will test the new range.
Watch forQ3 Cortrophin Gel sales reach at least $130M, keeping the company on pace for its $520M–$540M full-year range.
Also watch forQ3 Cortrophin Gel sales fall below $120M, putting the $520M full-year floor at risk.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$135 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $310 loss on $10,000 · 3.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,483 loss on $10,000 · 24.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.